• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Chu Shelley

    4/30/25 7:00:15 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HLVX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Chu Shelley

    (Last) (First) (Middle)
    C/O HILLEVAX, INC.,
    321 HARRISON AVE, SUITE 500

    (Street)
    BOSTON MA 02118

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HilleVax, Inc. [ HLVX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/06/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $13.75 06/06/2024 A 22,500 (1) 06/05/2034 Common Stock 22,500 $0 22,500 D
    Explanation of Responses:
    1. The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates.
    /s/ Paul Bavier, Attorney-in-Fact for Shelley Chu 04/30/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HLVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLVX

    DatePrice TargetRatingAnalyst
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    7/8/2024Buy → Neutral
    Guggenheim
    7/8/2024$24.00 → $5.00Overweight → Neutral
    JP Morgan
    12/13/2023$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $HLVX
    Financials

    Live finance-specific insights

    See more
    • HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

      BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date:  Tuesday, September 6, 2022Time:  1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator:  Eric Joseph, Ph.D.HilleVax Participant:  Robert Hershberg, M.D., Ph.D.,

      9/1/22 5:18:14 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    SEC Filings

    See more
    • SEC Form 10-Q filed by HilleVax Inc.

      10-Q - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:10:20 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:05:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13D filed by HilleVax Inc.

      SCHEDULE 13D - HilleVax, Inc. (0001888012) (Subject)

      5/2/25 4:15:10 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      $159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2025. First Quarter Financial Results As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and

      5/8/25 7:00:30 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

      $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024. Full Year 2024 Financial Results As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 mi

      3/28/25 5:00:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gerberding Julie L.

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:12 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chu Shelley

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:15 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Hilleman Jeryl L

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:11 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Leadership Updates

    Live Leadership Updates

    See more

    $HLVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

      Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

      5/9/24 4:05:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

      BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le

      1/18/24 7:00:00 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:36:33 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:00:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by HilleVax Inc.

      SC 13G - HilleVax, Inc. (0001888012) (Subject)

      7/22/24 9:02:05 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Frazier Life Sciences X, L.P. bought $128,325 worth of shares (8,850 units at $14.50) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/8/24 4:22:13 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcloughlin Sean bought $21,225 worth of shares (1,250 units at $16.98) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/1/24 4:08:42 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HilleVax downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

      7/9/24 9:48:14 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by Stifel with a new price target

      Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously

      7/9/24 7:46:22 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously

      7/9/24 7:46:01 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care